<p>瑞典银行（Swedbank AB）在第三季度减少了对 Medpace Holdings, Inc.（NASDAQ:MEDP - 免费报告）的持股比例，减少幅度为 18.3%，根据该公司最近向证券交易委员会（SEC）提交的 13F 表格。该公司在季度内出售了 13,000 股后，持有 58,000 股该公司的股票。瑞典银行在最近一个季度末持有的 Medpace 股份约占 0.21%，价值 29,821,000 美元。</p>
<ul>
<li>Medpace 股票能否保持这种增长速度？</li>
</ul>
<p>其他机构投资者最近也对该公司的股份进行了增持或减持。Wasatch Advisors LP 在第二季度将其在 Medpace 的持股比例提高了 14.0%。Wasatch Advisors LP 现在拥有 945,814 股该公司的股票，价值 296,853,000 美元，此前在上个季度又购买了 116,354 股。Mawer Investment Management Ltd.在第二季度将其在 Medpace 的持股提高了 17.4%。Mawer Investment Management Ltd.现在拥有 817,432 股该公司的股票，价值 256,559,000 美元，此前又收购了 121,213 股。AQR Capital Management LLC 在第二季度将其在 Medpace 的持股提高了 15.1%。AQR Capital Management LLC 现在拥有 621,184 股该公司的股票，价值 193,269,000 美元，此前又收购了 81,637 股。TD Asset Management Inc 在第二季度将其在 Medpace 的持股提高了 15.6%。TD Asset Management Inc 现在拥有 457,645 股该公司的股票，价值 143,636,000 美元，此前又收购了 61,764 股。最后，Epoch Investment Partners Inc.在第二季度将其在 Medpace 的持股提高了 11.4%。Epoch Investment Partners Inc.现在拥有 445,231 股该公司的股票，价值 139,740,000 美元，此前又购买了 45,435 股。机构投资者持有该公司 77.98% 的股份。</p>
<h2>分析师评级变动</h2>
<p>几家券商最近对 MEDP 发布了报告。Zacks Research 在 10 月 27 日的报告中将 Medpace 的评级从 “持有” 上调至 “强力买入”。Rothschild &amp; Co Redburn 在 9 月 3 日的研究报告中将 Medpace 的评级从 “买入” 下调至 “中性”，并将其目标价格从 342.00 美元上调至 474.00 美元。Cowen 在 10 月 24 日的研究报告中重申了对 Medpace 的 “卖出” 评级。Truist Financial 在 10 月 27 日的报告中设定了 Medpace 的价格目标为 555.00 美元。最后，Weiss Ratings 在 10 月 31 日的研究报告中重申了对 Medpace 的 “买入（b）” 评级。一位分析师对该股票给予了强力买入评级，两位给予了买入评级，十位给予了持有评级，四位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价格为 490.82 美元。</p>
<p><strong>查看我们最新的 Medpace 股票报告</strong></p>
<h2>Medpace 股票上涨 0.4%</h2>
<p>MEDP 股票在周五开盘价为 572.00 美元。该公司的 50 日简单移动平均线为 578.83 美元，200 日简单移动平均线为 478.30 美元。该公司的市值为 161.1 亿美元，市盈率为 40.00，PEG 比率为 2.16，贝塔值为 1.43。Medpace Holdings, Inc.的 52 周低点为 250.05 美元，52 周高点为 626.26 美元。</p>
<p>Medpace（NASDAQ:MEDP - 获取免费报告）在 10 月 22 日发布了其财报。该公司报告本季度每股收益为 3.86 美元，超出市场共识预期的 3.50 美元，超出幅度为 0.36 美元。Medpace 的净利润率为 18.36%，股本回报率为 91.88%。该公司本季度的收入为 6.599 亿美元，而分析师预期为 6.4049 亿美元。去年同期，该公司每股收益为 3.01 美元。Medpace 的季度收入同比增长 23.7%。Medpace 已将其 2025 财年的指引设定为每股收益 14.600-14.860 美元。股票分析师预计 Medpace Holdings, Inc.今年将发布每股收益 12.29 美元。</p>
<h2>内部买卖</h2>
<p>在其他消息中，首席财务官 Kevin M. Brady 在 11 月 21 日的交易中出售了 3,000 股公司的股票。股票以 590.35 美元的平均价格出售，总价值为 1,771,050.00 美元。出售后，首席财务官持有 6,000 股公司的股票，价值约为 3,542,100 美元。此次交易使其持股比例减少了 33.33%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，首席执行官 August J. Troendle 在 12 月 3 日的交易中出售了 668 股公司的股票。股票以 590.69 美元的平均价格出售，总价值为 394,580.92 美元。出售完成后，首席执行官持有 646,184 股公司的股票，价值约为 381,694,426.96 美元。此次交易使其持股比例减少了 0.10%。该出售的 SEC 备案提供了更多信息。内部人士在上个季度共出售了 387,925 股公司股票，价值 233,386,647 美元。公司内部人士持有该公司 20.30% 的股份。</p>
<h2>关于 Medpace</h2>
<p>（免费报告）</p>
<p>Medpace Holdings, Inc.（NASDAQ: MEDP）是一家全球合同研究组织（CRO），为生物技术、制药和医疗器械公司提供全面的临床开发服务。该公司支持所有阶段（I-IV）的临床试验，提供旨在简化开发过程并加速新疗法上市的端到端解决方案。</p>
<p>Medpace 的核心服务包括临床药理学、监管事务咨询、项目管理、中央实验室服务、影像学、数据管理和生物统计学、药物警戒和医学写作。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Medpace</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于 Medpace 吗？</h2>
<p>在考虑 Medpace 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Medpace 并不在名单上。</p>
<p>虽然 Medpace 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Medpace控股

<p>Swedbank AB 在第三季度减少了对 Medpace Holdings, Inc. 的持股比例，下降了 18.3%，目前持有 58,000 股，价值 2982 万美元。其他机构投资者也调整了他们的持仓，Wasatch Advisors、Mawer Investment、AQR Capital、TD Asset Management 和 Epoch Investment Partners 增加了他们的持股。Medpace 的股票获得了一致的 “持有” 评级，目标价格为 490.82 美元。该公司报告了强劲的第三季度业绩，收入同比增长 23.7%</p>

<p>Swedbank AB lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 18.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,000 shares of the company's stock after selling 13,000 shares during the quarter. Swedbank AB owned approximately 0.21% of Medpace worth $29,821,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>瑞典银行（Swedbank AB）在第三季度减少了对 Medpace Holdings, Inc.（NASDAQ:MEDP - 免费报告）的持股比例，减少幅度为 18.3%，根据该公司最近向证券交易委员会（SEC）提交的 13F 表格。该公司在季度内出售了 13,000 股后，持有 58,000 股该公司的股票。瑞典银行在最近一个季度末持有的 Medpace 股份约占 0.21%，价值 29,821,000 美元。</p>
</div><ul>
<li>Can Medpace Stock Keep up this Pace?</li>
</ul>
<div class="lb-trans"><ul>
<li>Medpace 股票能否保持这种增长速度？</li>
</ul>
</div><p>Other institutional investors have also recently added to or reduced their stakes in the company. Wasatch Advisors LP lifted its position in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Mawer Investment Management Ltd. lifted its holdings in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock worth $256,559,000 after acquiring an additional 121,213 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Medpace by 15.1% in the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company's stock worth $193,269,000 after acquiring an additional 81,637 shares during the last quarter. TD Asset Management Inc boosted its stake in Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company's stock valued at $143,636,000 after acquiring an additional 61,764 shares during the period. Finally, Epoch Investment Partners Inc. grew its holdings in shares of Medpace by 11.4% during the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company's stock valued at $139,740,000 after purchasing an additional 45,435 shares during the last quarter. Institutional investors own 77.98% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也对该公司的股份进行了增持或减持。Wasatch Advisors LP 在第二季度将其在 Medpace 的持股比例提高了 14.0%。Wasatch Advisors LP 现在拥有 945,814 股该公司的股票，价值 296,853,000 美元，此前在上个季度又购买了 116,354 股。Mawer Investment Management Ltd.在第二季度将其在 Medpace 的持股提高了 17.4%。Mawer Investment Management Ltd.现在拥有 817,432 股该公司的股票，价值 256,559,000 美元，此前又收购了 121,213 股。AQR Capital Management LLC 在第二季度将其在 Medpace 的持股提高了 15.1%。AQR Capital Management LLC 现在拥有 621,184 股该公司的股票，价值 193,269,000 美元，此前又收购了 81,637 股。TD Asset Management Inc 在第二季度将其在 Medpace 的持股提高了 15.6%。TD Asset Management Inc 现在拥有 457,645 股该公司的股票，价值 143,636,000 美元，此前又收购了 61,764 股。最后，Epoch Investment Partners Inc.在第二季度将其在 Medpace 的持股提高了 11.4%。Epoch Investment Partners Inc.现在拥有 445,231 股该公司的股票，价值 139,740,000 美元，此前又购买了 45,435 股。机构投资者持有该公司 77.98% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several brokerages recently issued reports on MEDP. Zacks Research raised Medpace from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, October 27th. Rothschild &amp; Co Redburn cut Medpace from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and raised their target price for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Cowen restated a &#34;sell&#34; rating on shares of Medpace in a research report on Friday, October 24th. Truist Financial set a $555.00 price objective on shares of Medpace in a report on Monday, October 27th. Finally, Weiss Ratings reiterated a &#34;buy (b)&#34; rating on shares of Medpace in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $490.82.</p>
<div class="lb-trans"><p>几家券商最近对 MEDP 发布了报告。Zacks Research 在 10 月 27 日的报告中将 Medpace 的评级从 “持有” 上调至 “强力买入”。Rothschild &amp; Co Redburn 在 9 月 3 日的研究报告中将 Medpace 的评级从 “买入” 下调至 “中性”，并将其目标价格从 342.00 美元上调至 474.00 美元。Cowen 在 10 月 24 日的研究报告中重申了对 Medpace 的 “卖出” 评级。Truist Financial 在 10 月 27 日的报告中设定了 Medpace 的价格目标为 555.00 美元。最后，Weiss Ratings 在 10 月 31 日的研究报告中重申了对 Medpace 的 “买入（b）” 评级。一位分析师对该股票给予了强力买入评级，两位给予了买入评级，十位给予了持有评级，四位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价格为 490.82 美元。</p>
</div><p><strong>View Our Latest Stock Report on Medpace</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Medpace 股票报告</strong></p>
</div><h2>Medpace Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Medpace 股票上涨 0.4%</h2>
</div><p>MEDP stock opened at $572.00 on Friday. The company has a 50-day simple moving average of $578.83 and a 200 day simple moving average of $478.30. The company has a market capitalization of $16.11 billion, a P/E ratio of 40.00, a PEG ratio of 2.16 and a beta of 1.43. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26.</p>
<div class="lb-trans"><p>MEDP 股票在周五开盘价为 572.00 美元。该公司的 50 日简单移动平均线为 578.83 美元，200 日简单移动平均线为 478.30 美元。该公司的市值为 161.1 亿美元，市盈率为 40.00，PEG 比率为 2.16，贝塔值为 1.43。Medpace Holdings, Inc.的 52 周低点为 250.05 美元，52 周高点为 626.26 美元。</p>
</div><p>Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to analysts' expectations of $640.49 million. During the same quarter last year, the company earned $3.01 EPS. Medpace's quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.</p>
<div class="lb-trans"><p>Medpace（NASDAQ:MEDP - 获取免费报告）在 10 月 22 日发布了其财报。该公司报告本季度每股收益为 3.86 美元，超出市场共识预期的 3.50 美元，超出幅度为 0.36 美元。Medpace 的净利润率为 18.36%，股本回报率为 91.88%。该公司本季度的收入为 6.599 亿美元，而分析师预期为 6.4049 亿美元。去年同期，该公司每股收益为 3.01 美元。Medpace 的季度收入同比增长 23.7%。Medpace 已将其 2025 财年的指引设定为每股收益 14.600-14.860 美元。股票分析师预计 Medpace Holdings, Inc.今年将发布每股收益 12.29 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, CFO Kevin M. Brady sold 3,000 shares of the business's stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 668 shares of the company's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company's stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 387,925 shares of company stock valued at $233,386,647 over the last quarter. Corporate insiders own 20.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Kevin M. Brady 在 11 月 21 日的交易中出售了 3,000 股公司的股票。股票以 590.35 美元的平均价格出售，总价值为 1,771,050.00 美元。出售后，首席财务官持有 6,000 股公司的股票，价值约为 3,542,100 美元。此次交易使其持股比例减少了 33.33%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，首席执行官 August J. Troendle 在 12 月 3 日的交易中出售了 668 股公司的股票。股票以 590.69 美元的平均价格出售，总价值为 394,580.92 美元。出售完成后，首席执行官持有 646,184 股公司的股票，价值约为 381,694,426.96 美元。此次交易使其持股比例减少了 0.10%。该出售的 SEC 备案提供了更多信息。内部人士在上个季度共出售了 387,925 股公司股票，价值 233,386,647 美元。公司内部人士持有该公司 20.30% 的股份。</p>
</div><h2>About Medpace</h2>
<div class="lb-trans"><h2>关于 Medpace</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.</p>
<div class="lb-trans"><p>Medpace Holdings, Inc.（NASDAQ: MEDP）是一家全球合同研究组织（CRO），为生物技术、制药和医疗器械公司提供全面的临床开发服务。该公司支持所有阶段（I-IV）的临床试验，提供旨在简化开发过程并加速新疗法上市的端到端解决方案。</p>
</div><p>Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.</p>
<div class="lb-trans"><p>Medpace 的核心服务包括临床药理学、监管事务咨询、项目管理、中央实验室服务、影像学、数据管理和生物统计学、药物警戒和医学写作。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Medpace</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Medpace</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MEDP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Medpace Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于 Medpace 吗？</h2>
</div><p>Before you consider Medpace, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Medpace 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Medpace 并不在名单上。</p>
</div><p>While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Medpace 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Swedbank AB 出售了 Medpace 控股公司的$MEDP 股票